Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with one histologically confirmed superficial and nodular basal cell carcinoma (8-20 mm) eligible for surgical excision on selected body areas (scalp, arm, frontal trunk, posterior trunk, upper legs)~Exclusion Criteria:~* Previous treatment of the sBCC that are selected for treatment.~* Any systemic treatment which is known to affect BCCs esp. cytostatic treatments, retinoids and photodynamic treatments.~* Dark-skinned persons whose skin color prevents readily assessment of skin reactions~Other protocol defined Incl./Excl. criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- LDE225 0.75% (Type: EXPERIMENTAL): Participants topically applied 0.75% LDE225 cream twice daily for 6 weeks.
- Vehicle (Type: PLACEBO_COMPARATOR): Participants topically applied matching placebo cream twice daily for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).